MultiHance® 9 Image Library 9 Seidl et al. 58F Metastatic Melanoma

MultiHance® (gadobenate dimeglumine) injection, 529 mg/mL vs. Gadavist® (gadobutrol)1

The MERIT Study
Seidl et al.
58-year-old woman with metastatic melanoma

These are representative images from reference studies; individual results may vary.
Reference: 1. Seidl Z, Vymazal J, Mechi M, et al. Does higher gadolinium concentration play a role in the morphologic assessment of brain tumors? Results of a multicenter intraindividual crossover comparison of gadobutrol versus gadobenate dimeglumine (the MERIT Study). AJNR Am J Neuroradiol. 2012;33(6):1050-1058.

View Full Image Library

More cases that may interest you

Seidl et al. 70M Metastatic Lung Carcinoma

Seidl et al. 70M Metastatic Lung Carcinoma

Seidl et al. 58F Metastatic Melanoma

Seidl et al. 58F Metastatic Melanoma

Rowley et al. 55F Glioblastoma with Recurrent Disease

Rowley et al. 55F Glioblastoma with Recurrent Disease